Arizona State Retirement System raised its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 2.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 562,663 shares of the company's stock after acquiring an additional 15,898 shares during the period. Arizona State Retirement System's holdings in Kenvue were worth $13,493,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of KVUE. Cambridge Investment Research Advisors Inc. increased its stake in Kenvue by 4.0% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after acquiring an additional 4,034 shares during the last quarter. Starboard Value LP purchased a new stake in Kenvue in the 4th quarter worth about $467,864,000. TrueMark Investments LLC lifted its stake in Kenvue by 9.3% in the fourth quarter. TrueMark Investments LLC now owns 190,595 shares of the company's stock worth $4,069,000 after purchasing an additional 16,161 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new position in shares of Kenvue during the first quarter valued at approximately $413,000. Finally, DLK Investment Management LLC purchased a new stake in shares of Kenvue in the first quarter worth approximately $4,100,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Stock Performance
Shares of Kenvue stock traded up $0.53 during midday trading on Monday, hitting $21.87. The company had a trading volume of 58,611,406 shares, compared to its average volume of 16,239,743. The stock has a market cap of $41.96 billion, a price-to-earnings ratio of 39.76, a PEG ratio of 3.32 and a beta of 0.83. Kenvue Inc. has a 12-month low of $17.85 and a 12-month high of $25.17. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. The company has a fifty day simple moving average of $22.34 and a 200 day simple moving average of $22.30.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The company's revenue was down 3.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.28 earnings per share. As a group, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.75%. The ex-dividend date of this dividend was Wednesday, May 14th. Kenvue's dividend payout ratio is currently 149.09%.
Analysts Set New Price Targets
Several equities analysts have commented on the company. UBS Group upped their price objective on Kenvue from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Friday, May 9th. Evercore ISI started coverage on shares of Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Barclays lifted their price target on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research note on Monday, May 12th. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Finally, Redburn Atlantic assumed coverage on shares of Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price objective for the company. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $25.33.
Check Out Our Latest Research Report on KVUE
Kenvue Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
